FDA Panel To Discuss “Breakpoint” Changes For Systemic Antibiotics
This article was originally published in The Pink Sheet Daily
Anti-Infective Drugs Advisory Committee will meet Oct. 17 to discuss whether and when it is appropriate to base susceptibility test interpretive criteria on the highest or lowest approved dose of a drug, or whether labeling should reflect breakpoints specific to each approved dosing regimen and indication.
You may also be interested in...
Cubist’s second-generation oxazolidineone is set for an FDA advisory committee review in March.
In certain circumstances it may be appropriate to change the criteria for determining when a pathogen is susceptible to a drug and recommended doses for systemic antibacterials absent clinical outcomes data, Anti-Infective Drugs Advisory Committee says.
FDA plans to issue a yearly update on the susceptibility of bacteria to treatment by individual antibiotics and has drafted guidance that calls on drug makers to revise labeling for systemic antibacterial products accordingly